You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDinoprost Tromethamine
Accession NumberDB01160  (APRD00926)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionThe tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.
Structure
Thumb
Synonyms
Dinoprost trometamol
PGF2-alpha THAM
PGF2alpha THAM
Prostaglandin F2-alpha THAM
Prostaglandin F2a tromethamine
Prostaglandin F2alpha tham
Prostin F2 Alpha
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prostin F2 AlphaSolution5 mgIntra-amnioticPfizer Canada Inc1974-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DinolyticPfizer
Enzaprost FChinoin
ProsmonFuji Yakuhin
Prostin F2 AlphaPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNIICT6BBQ5A68
CAS number38562-01-5
WeightAverage: 475.616
Monoisotopic: 475.314517421
Chemical FormulaC24H45NO8
InChI KeyIYGXEHDCSOYNKY-RZHHZEQLSA-N
InChI
InChI=1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1
IUPAC Name
(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoic acid; 2-amino-2-(hydroxymethyl)propane-1,3-diol
SMILES
OCC(N)(CO)CO.CCCCC[[email protected]](O)\C=C\[[email protected]]1[[email protected]](O)C[[email protected]](O)[C@@H]1C\C=C/CCCC(O)=O
Pharmacology
IndicationUsed for aborting second-trimester pregnancy (between the twelfth to eighteenth week of gestation) and in incomplete abortion or for therapeutic abortion in cases of intrauterine fetal death and congenital abnormalities incompatible with life. Also used at low-doses for medically indicated induction of labor at term. Also injected intra-arterially for use as a vasodilator to assist in angiography.
Structured Indications Not Available
PharmacodynamicsDinoprost tromethamine is the tromethamine (THAM) salt of the naturally occurring prostaglandin F2alpha. Prostaglandin F2alpha has several pharmacologic effects on the female reproductive system, including stimulation of myometrial activity, relaxation of the cervix, inhibition of steroidogenesis by corpora lutea, and can potentially lyse corpora lutea.
Mechanism of actionDinoprost tromethamine appears to act directly on the myometrium, but this has not been completely established. Dinoprost stimulates myometrial contractions (via its interaction with the prostaglandin receptors) in the gravid uterus that are similar to the contractions that occur in the term uterus during labor. These contractions are usually sufficient to cause abortion. Uterine response to prostaglandins increases gradually throughout pregnancy. Dinoprost also facilitates cervical dilatation and softening.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin F2-alpha receptorProteinyes
agonist
HumanP43088 details
Prostacyclin receptorProteinunknown
antagonist
HumanP43119 details
Related Articles
AbsorptionSlowly absorbed from the amniotic fluid into systemic circulation.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Enzymatic dehydrogenation primarily in the maternal lungs and also in the liver.

Route of eliminationNot Available
Half lifeThe half-life of dinoprost in amniotic fluid is 3 to 6 hours. The plasma half-life of dinoprost after intravenous administration is reported to be less than 1 minute.
ClearanceNot Available
ToxicityAlthough overdose by intra-amniotic administration of dinoprost has not been reported, exaggeration of the nausea, vomiting, and diarrhea that occur with normal doses would be expected.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AceclofenacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Aceclofenac.Approved
AcetovanilloneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Acetovanillone.Investigational
Acetylsalicylic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Adapalene.Approved
AnisodamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Antipyrine.Approved
ApremilastThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Apremilast.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Balsalazide.Approved, Investigational
BenoxaprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Benoxaprofen.Withdrawn
Betulinic AcidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Betulinic Acid.Investigational
BromfenacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bucillamine.Investigational
Carboprost TromethamineThe risk or severity of adverse effects can be increased when Carboprost Tromethamine is combined with Dinoprost Tromethamine.Approved
CarprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Celecoxib.Approved, Investigational
ChloroquineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ClonixinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Clonixin.Approved
CurcuminThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Curcumin.Investigational
D-LimoneneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with D-Limonene.Investigational
DiclofenacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiflunisalThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Diflunisal.Approved
DroxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Droxicam.Approved
DuvelisibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ebselen.Investigational
EpirizoleThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Epirizole.Approved
EtanerceptThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etanercept.Approved, Investigational
EtodolacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etofenamate.Approved
EtoricoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Evening primrose oil.Approved
exisulindThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with exisulind.Investigational
FenbufenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Fenoprofen.Approved
FloctafenineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FlunixinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Flunixin.Vet Approved
FlurbiprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
HigenamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with HMPL-004.Investigational
IbuprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Icatibant.Approved
IndomethacinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Indoprofen.Withdrawn
IsoxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Kebuzone.Experimental
KetoprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketorolac.Approved
LeflunomideThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Leflunomide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lisofylline.Investigational
LornoxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lornoxicam.Approved
LoxoprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Masoprocol.Approved
Meclofenamic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mefenamic acid.Approved
MeloxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Metamizole.Withdrawn
MizoribineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mizoribine.Investigational
Mycophenolate mofetilThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Naftifine.Approved
NaproxenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 4016The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with NCX 4016.Investigational
NepafenacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nepafenac.Approved
Niflumic AcidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NitroaspirinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nitroaspirin.Investigational
OlopatadineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olsalazine.Approved
OrgoteinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Orgotein.Vet Approved
OxaprozinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Oxyphenbutazone.Withdrawn
ParecoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Parecoxib.Approved
PhenylbutazoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Pirfenidone.Investigational
PiroxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Piroxicam.Approved, Investigational
PropacetamolThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Propacetamol.Approved
PTC299The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with PTC299.Investigational
ResveratrolThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Resveratrol.Experimental, Investigational
RofecoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
SalicylamideThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Salsalate.Approved
SeratrodastThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Seratrodast.Approved, Investigational
SRT501The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with SRT501.Investigational
SulfasalazineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Sulindac.Approved
SuprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Suprofen.Approved, Withdrawn
TenoxicamThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tiaprofenic acid.Approved
TinoridineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tinoridine.Investigational
Tolfenamic AcidThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tolmetin.Approved
TranilastThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Tranilast.Approved, Investigational
Trisalicylate-cholineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Trisalicylate-choline.Approved
ValdecoxibThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Morozowich, W.; U.S. Patent 3,657,327; April 18,1972; assigned to The Upjohn Company.

General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 76:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (51.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9588
Blood Brain Barrier-0.6473
Caco-2 permeable-0.674
P-glycoprotein substrateSubstrate0.6903
P-glycoprotein inhibitor INon-inhibitor0.9204
P-glycoprotein inhibitor IINon-inhibitor0.9821
Renal organic cation transporterNon-inhibitor0.8743
CYP450 2C9 substrateNon-substrate0.838
CYP450 2D6 substrateNon-substrate0.7753
CYP450 3A4 substrateNon-substrate0.5576
CYP450 1A2 substrateNon-inhibitor0.6725
CYP450 2C9 inhibitorNon-inhibitor0.9145
CYP450 2D6 inhibitorNon-inhibitor0.764
CYP450 2C19 inhibitorNon-inhibitor0.8258
CYP450 3A4 inhibitorNon-inhibitor0.9349
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9466
Ames testNon AMES toxic0.9033
CarcinogenicityNon-carcinogens0.9383
BiodegradationNot ready biodegradable0.7399
Rat acute toxicity2.1479 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9677
hERG inhibition (predictor II)Non-inhibitor0.8921
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
SolutionIntra-amniotic5 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point100-101Morozowich, W.; U.S. Patent 3,657,327; April 18,1972; assigned to The Upjohn Company.
water solubility0.2 g/mLNot Available
logP-0.12Not Available
Predicted Properties
PropertyValueSource
logP2.61ChemAxon
pKa (Strongest Acidic)4.36ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area97.99 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity100.47 m3·mol-1ChemAxon
Polarizability41.56 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassFatty Acyls
Sub ClassEicosanoids
Direct ParentProstaglandins and related compounds
Alternative Parents
Substituents
  • Prostaglandin skeleton
  • Long-chain fatty acid
  • Hydroxy fatty acid
  • Carbocyclic fatty acid
  • Fatty acid
  • Unsaturated fatty acid
  • Cyclopentanol
  • Cyclic alcohol
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aliphatic homomonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Prostaglandin f receptor activity
Specific Function:
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and ...
Gene Name:
PTGFR
Uniprot ID:
P43088
Molecular Weight:
40054.1 Da
References
  1. Sakamoto K, Kamimura M, Kurozumi S, Ito S: Prostaglandin F2 alpha receptor. J Lipid Mediat Cell Signal. 1995 Oct;12(2-3):405-11. [PubMed:8777582 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name:
PTGIR
Uniprot ID:
P43119
Molecular Weight:
40955.485 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Quaternary ammonium group transmembrane transporter activity
Specific Function:
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridiniu...
Gene Name:
SLC22A2
Uniprot ID:
O15244
Molecular Weight:
62579.99 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:
SLC22A8
Uniprot ID:
Q8TCC7
Molecular Weight:
59855.585 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:
SLC22A11
Uniprot ID:
Q9NSA0
Molecular Weight:
59970.945 Da
References
  1. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. [PubMed:11907186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A.
Gene Name:
SLCO2A1
Uniprot ID:
Q92959
Molecular Weight:
70043.33 Da
References
  1. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. [PubMed:8787677 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 and vasopressin, but not DPDPE (a derivative of enkephalin lacking an N-terminal tyrosine residue), estrone-3-sulfate, taurocholate, digoxin nor DHEAS (PubMed:16971491).
Gene Name:
SLCO3A1
Uniprot ID:
Q9UIG8
Molecular Weight:
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23